Skip to main
ANGO
ANGO logo

AngioDynamics (ANGO) Stock Forecast & Price Target

AngioDynamics (ANGO) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AngioDynamics Inc. is experiencing growth in its Auryon product line, which is expanding its customer base in both the office-based lab (OBL) and hospital settings, significantly benefiting average selling prices (ASP). The company is also on track to enhance its gross margins, currently reported at 52.5%, through improved manufacturing initiatives and a favorable shift towards higher Med-Tech revenues, with completion anticipated by January 2026. Furthermore, management suggests that continued customer acquisition, increasing utilization within existing accounts, and successful pricing strategies will support ongoing growth for key product offerings.

Bears say

AngioDynamics Inc is anticipating $4 million to $6 million in tariff-related headwinds, which could negatively impact future financial performance. Furthermore, the company expects inventory pressure in the second half of fiscal 2026 due to rising raw material costs, which may strain margins and overall profitability. These factors, alongside reliance on capital sales to drive future disposable demand, suggest an unstable outlook for the company's financial stability.

AngioDynamics (ANGO) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AngioDynamics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AngioDynamics (ANGO) Forecast

Analysts have given AngioDynamics (ANGO) a Strong Buy based on their latest research and market trends.

According to 3 analysts, AngioDynamics (ANGO) has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AngioDynamics (ANGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.